Industry News
New trial for Progen melanoma therapy
Queensland oncology drug-discovery company Progen Industries has begun a new Phase I/II clinical study of its lead anti-cancer compound PI-88 in patients with malignant melanoma. [ + ]
Eqitx, Vaccine CRC join to take vaccine to market
Perth-based biotechnology company EqiTX (ASX:EQX) and the CRC for Vaccine Technology (CRC-VT) have joined forces to develop and commercialise the CRC's lipopeptide vaccine technology. [ + ]
BioDiem to float next week after IPO success
BioDiem is looking forward to floating on the ASX on January 27, after successfully raising AUD$8.5 million through an IPO. [ + ]
Adelaide Uni heads up new mineral exploration initiative
The University of Adelaide has successfully attracted $576,000 worth of funding from the Australian Research Council to research the mineral exploration potential of South Australia's Gawler Craton area.
[ + ]Protein could predict women who will miscarry
A protein found in the placenta of pregnant women could be used to predict whether they will miscarry their babies, Monash University/Monash Medical Centre researchers working with scientists at St Vincent's Hospital, Sydney, have found.
[ + ]Australian Innovation at the Speed of Light
CSIRO has announced its commitment of $5M to the Australian Synchrotron facility (AS) heralding its participation in the $206M facility as a Foundation Partner.
[ + ]Green light for new plant technology
Brilliant green turf all-year round, needing less maintenance and mowing, could soon be available through technology developed at The University of Queensland.
[ + ]Macquarie supports Australian involvement in space exploration
Macquarie University's Australian Centre for Astrobiology (ACA) has supported a recommendation by a new consortium of Australian space-related organisations that the Federal Government help maximise Australia's involvement in the future of space exploration by setting up an Australian space agency.
[ + ]RMIT researchers tackle deadly plant
RMIT researchers are investigating a poisonous weed that threatens native Australian animals and livestock and could pose a serious public health risk.
[ + ]BresaGen goes into voluntary administration
Australian biotechnology veteran BresaGen (ASX:BGN) has gone into voluntary administration. [ + ]
Bionomics reports healthy bank balance
Adelaide biotech Bionomics (ASX:BNO) has reported that it had nearly AUD$5 million in the bank at the end of the December 2003 quarter, giving it enough cash for at least two years at its current burn rate. [ + ]
CSL, Chiron move to Phase II hep C vaccine trial
The hopes of hundreds of thousands of people around the world chronically infected with hepatitis C virus could be riding on an Australian clinical trial of a new, potentially life-saving vaccine being jointly developed by US-based Chiron Corporation and Melbourne pharmaceutical company CSL (ASX:CSL). [ + ]
Fewer farmer objections to GM crops
A national survey of Australian farmers' views on genetically modified (GM) crops has identified a marked shift in sentiment during the past 12 months, with fewer farmers now opposed. [ + ]
Biotron wins Start grant for virus blocker trials
Canberra biotechnology company Biotron (ASX:BIT) has been offered a $1.66 million Commonwealth R&D Start grant to begin clinical development and testing of novel compounds designed to disrupt replication of the AIDS virus. [ + ]
UNSW spin-off Biosignal to list in reverse takeover
Biosignal, a spin-off from the University of NSW, is to list on the ASX in late March through a reverse takeover of CTI Communications (ASX:CTC), a telecommunications services company. [ + ]
